Bioelectronics Corp (BIEL)

[4toSchool]

Russia, Ukraine, and S. Africa have all been mentioned numerous times, although not since January.

It is really interesting to see that in May 2019 we were told that BIEL had "signed deals in place." Then in December 2019, we're told that "Negotiations also continue", and in January 2020 we were told
that they were "working to finalize deals", and most recently that "discussions are ongoing".

NORMAL COMPANIES follow this sales process:

Step #1. Discussions with potential clients
Step #3. Negotiations continue
Step #2. Finalize the deal
Step #4. Signed contract in place

Now: the sequence we're told by BIEL management is backward.

BIEL's sales process:

Step #1. Signed contract in place
Step #3. Negotiations continue
Step #2. Finalize the deal
Step #4. Discussions with potential clients
Step #5. Never mention these potential partners ever again. Leave shareholders in the dark because "ignorance is bliss".

News From BioElectronics: Tue, May 21, 2019

Good news from BIEL: In Europe we have also now added Russia and the Ukraine with large pharmaceutical companies of which we have signed deals in place. These deals in Russia and the Ukraine also come with over 200 sales reps who will be promoting Actipatch all over both of those countries. We have maintained our wholesale pricing with both entities and are in a strong position to market to large populations.

BioElectronics Investor Update Mon, Dec 16, 2019

our discussions to expand territories with Mundipharma are ongoing and we believe our demonstrated ability to deliver 15k products to the SEA region will positively impact our ability to close a contract for the MENA region. Negotiations also continue with our potential partners in both Russia and South America.

BioElectronics Investor Update Mon, Jan 6, 2020

in 180 days from my father's passing, we will be a Company with multiple major partners, growing revenue and increased shareholder value. Internationally, we are continuing to build on the momentum with our recent shipments to MundiPharma SEA– they have received product and are preparing to launch. Additionally, we are working to finalize deals with large companies for distribution in the Russian and South African markets. Further, we are investigating an opportunity to renew sales in the UK with the help of a US-based partner who has strong relationships in the UK retail market.

E & E Communications Investor Updates January 20, 2020

the FDA provided several recommendations on how to continuously improve quality management and ensure global compliance, given that the Company’s products are exported to distributors in several continents such as MundiPharma SEA, and other potential distributors in Russia, South Africa and Ukraine with whom discussions are ongoing.

IT IS TIME FOR FRESH AND COMPETENT MANAGEMENT.